Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. news
  3. genomics s
Show results for

Refine by
Date

  • This month
  • This Year
  • Older

Genomics S Articles & Analysis

446 news found

Creative Diagnostics Announces Advanced Microbial Genome Editing Services to Accelerate Bio-research

Creative Diagnostics Announces Advanced Microbial Genome Editing Services to Accelerate Bio-research

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has introduced its efficient and precise Microbial Genome Editing services to support researchers in the modification of specific target genes within an organism's genome.Microbial cell factories are a promising mode of production for fuels, chemicals, and pharmaceuticals because microbial ...

ByCreative Diagnostics


SOPHiA Genetics Achieves ISO 27017 and ISO 27018 Certifications

SOPHiA Genetics Achieves ISO 27017 and ISO 27018 Certifications

These internationally recognized standards, developed and published by the world’s most recognized standards organization for information security management systems, underscore the Company’s commitment to maintaining the highest standards of security and data protection for its customers and the patients they serve. ...

BySOPHiA Genetics


Overcoming Data Quality Challenges in Next-Generation Sequencing for Metagenomics

Overcoming Data Quality Challenges in Next-Generation Sequencing for Metagenomics

Next-generation sequencing (NGS) has revolutionized the field of genomics by enabling researchers to generate vast amounts of sequence data in a single experiment. This technology is particularly valuable in applications such as metagenomics, where it allows for the analysis of complex microbial communities, such as those found in the human gut. However, despite its advantages, NGS is not without ...

ByCD Genomics


Ace Therapeutics Launches Gene Therapy Development Services to Unleash Glaucoma Drug Research

Ace Therapeutics Launches Gene Therapy Development Services to Unleash Glaucoma Drug Research

Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease. Glaucoma is a group of eye conditions that damage the optic nerve, often ...

ByAce Therapeutics


Protheragen-ING AI-Pharma’s AI-Powered Drug Discovery and Design Platform—A Paradigm Shift in Drug Development

Protheragen-ING AI-Pharma’s AI-Powered Drug Discovery and Design Platform—A Paradigm Shift in Drug Development

By integrating data from multiple sources, including genomics and proteomics, their AI models can identify unexplored targets, potentially accelerating the development of novel therapeutics. The paradigm shift introduced by Protheragen-ING AI-Pharma’s AI-powered tools marks a significant advancement in drug discovery. ...

ByProtheragen-ING


SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its ...

BySOPHiA Genetics


SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research

SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research

The two companies have expanded the integration of Genomenon’s Mastermind® Genomic Intelligence Platform into SOPHiA GENETICS’ Alamut™ Visual Plus, to empower researchers and clinical geneticists with a solution that helps accelerate variant interpretation for rare disorders. ...

BySOPHiA Genetics


Influenza A Virus Mouse Models for Accelerated Research

Influenza A Virus Mouse Models for Accelerated Research

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral treatments against influenza A infections. ...

ByCreative Diagnostics


H5N1 Antibodies and Antigens for Research Applications

H5N1 Antibodies and Antigens for Research Applications

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is excited to announce the launch of its new line of H5N1 Antibodies and Antigens to support cutting-edge research on this highly pathogenic influenza A virus subtype. These innovative products offer researchers and scientists invaluable tools for studying and combating the H5N1 influenza virus. ...

ByCreative Diagnostics


ECP Posters spotlight

ECP Posters spotlight

In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO ...

BySOPHiA Genetics


CDC Report: Burkholderia multivorans Infections Linked to Hospital Ice Machines

CDC Report: Burkholderia multivorans Infections Linked to Hospital Ice Machines

A Centers for Disease Control and Prevention (CDC) report published on October 3, 2024, linked Burkholderia multivorans infections to ice machines in multiple healthcare facilities in the western United States. This post summarizes key findings, implications, and recommended practices for healthcare providers to ensure patient ...

ByLiquitech, Inc.


SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

The SOPHiA GENETICS study used cutting-edge multimodal machine learning models to analyze clinical, biological, genomic, and imaging data, pinpointing patient subgroups who are most likely to benefit from the combination treatment. ...

BySOPHiA Genetics


SOPHiA Genetics and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA Genetics and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will ...

BySOPHiA Genetics


SOPHiA Genetics Announces It Joins the European Liquid Biopsy Society at ECP 2024

SOPHiA Genetics Announces It Joins the European Liquid Biopsy Society at ECP 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care. SOPHiA GENETICS offers a ...

BySOPHiA Genetics


SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection ...

BySOPHiA Genetics


SOPHiA Genetics Unveils New Generation of the SOPHiA DDM Platform at Morgan Stanley Healthcare Conference 2024

SOPHiA Genetics Unveils New Generation of the SOPHiA DDM Platform at Morgan Stanley Healthcare Conference 2024

Data computed daily by the Platform has surged over the years with over 1.8 million genomic profiles being analyzed on the platform, at a rate of almost 30,000 analyses per month. ...

BySOPHiA Genetics


CD Genomics Debuts Next-Generation Nanopore Sequencing Services for Unlocking Genomic Secrets

CD Genomics Debuts Next-Generation Nanopore Sequencing Services for Unlocking Genomic Secrets

CD Genomics, a leading provider of genomic research solutions, today announced the launch of its cutting-edge Nanopore sequencing services, marking a significant advancement in DNA and RNA analysis capabilities. This innovative technology, developed by Oxford Nanopore Technologies, is set to transform the landscape of life sciences research, offering unprecedented insights into genetic material. ...

ByCD Genomics


CD Genomics Unveils Advanced Whole Genome Sequencing Solutions for Comprehensive Genetic Insights

CD Genomics Unveils Advanced Whole Genome Sequencing Solutions for Comprehensive Genetic Insights

CD Genomics, a pioneering leader in genomic solutions, is proud to announce its cutting-edge whole genome sequencing (WGS) services. Utilizing the latest technologies from Illumina and PacBio platforms, CD Genomics offers precise and affordable sequencing solutions for a wide range of organisms, including viruses, microbes, plants, animals, and humans. Whole genome sequencing represents a ...

ByCD Genomics


Creative Diagnostics Announces High-Affinity Anti-Adenovirus Monoclonal Antibodies for Research and Assay Development

Creative Diagnostics Announces High-Affinity Anti-Adenovirus Monoclonal Antibodies for Research and Assay Development

Adenoviruses (members of the family Adenoviridae) are medium-sized (90-100 nm), nonenveloped viruses with icosahedral nucleocapsids containing a double-stranded DNA genome. The name derives from the first isolation of an adenovirus from human adenoids in 1953. ...

ByCreative Diagnostics


Tempus Announces the Clinical Launch of its MRD Testing Portfolio

Tempus Announces the Clinical Launch of its MRD Testing Portfolio

Hazard Ratio of 9.69 vs. 2.13) In late 2023, Tempus formed a strategic collaboration with Personalis, Inc., a leader in advanced genomics for precision oncology, to co-commercialize NeXT Personal® Dx, an ultra-sensitive, tumor-informed MRD and monitoring test based on whole genome sequencing offered by Personalis. ...

ByTempus

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT